Vestal Point Capital LP purchased a new position in shares of Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 2,570,000 shares of the company's stock, valued at approximately $4,729,000. Vestal Point Capital LP owned about 3.12% of Sutro Biopharma as of its most recent SEC filing.
Several other hedge funds have also recently added to or reduced their stakes in STRO. Dynamic Technology Lab Private Ltd bought a new stake in shares of Sutro Biopharma in the 4th quarter valued at about $26,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Sutro Biopharma in the 4th quarter valued at about $32,000. Vontobel Holding Ltd. lifted its stake in shares of Sutro Biopharma by 66.7% in the 4th quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company's stock valued at $46,000 after acquiring an additional 10,000 shares during the last quarter. ProShare Advisors LLC lifted its stake in shares of Sutro Biopharma by 74.3% in the 4th quarter. ProShare Advisors LLC now owns 26,961 shares of the company's stock valued at $50,000 after acquiring an additional 11,494 shares during the last quarter. Finally, Invesco Ltd. lifted its stake in shares of Sutro Biopharma by 54.2% in the 4th quarter. Invesco Ltd. now owns 38,749 shares of the company's stock valued at $71,000 after acquiring an additional 13,620 shares during the last quarter. Institutional investors own 96.99% of the company's stock.
Sutro Biopharma Stock Up 1.9%
NASDAQ:STRO traded up $0.02 on Friday, reaching $0.92. 721,581 shares of the company's stock traded hands, compared to its average volume of 1,094,156. The stock has a 50-day simple moving average of $0.78 and a 200-day simple moving average of $1.66. The firm has a market cap of $77.70 million, a PE ratio of -0.57 and a beta of 1.77. Sutro Biopharma, Inc. has a 12 month low of $0.52 and a 12 month high of $5.17.
Sutro Biopharma (NASDAQ:STRO - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.28). Sutro Biopharma had a negative return on equity of 101.89% and a negative net margin of 77.01%. The firm had revenue of $17.40 million during the quarter, compared to the consensus estimate of $11.61 million. On average, equities analysts anticipate that Sutro Biopharma, Inc. will post -2.92 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of research analysts recently issued reports on the company. Wedbush downgraded Sutro Biopharma from an "outperform" rating to a "neutral" rating and reduced their price target for the company from $8.00 to $2.00 in a report on Friday, March 14th. HC Wainwright restated a "neutral" rating and set a $2.00 price target on shares of Sutro Biopharma in a report on Tuesday, April 29th. Piper Sandler set a $2.00 price target on Sutro Biopharma in a report on Friday, March 14th. Citizens Jmp downgraded Sutro Biopharma from an "outperform" rating to a "market perform" rating in a report on Friday, March 14th. Finally, Bank of America reduced their price target on Sutro Biopharma from $1.00 to $0.80 and set an "underperform" rating on the stock in a report on Monday, May 19th. One research analyst has rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $6.11.
View Our Latest Report on Sutro Biopharma
About Sutro Biopharma
(
Free Report)
Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.
Further Reading
Before you consider Sutro Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sutro Biopharma wasn't on the list.
While Sutro Biopharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
